BEACON-CRC

NCT02928224 📎

Regimen

Experimental
Encorafenib + binimetinib + cetuximab (triplet); encorafenib + cetuximab (doublet)
Control
Investigator's choice (cetuximab + irinotecan or cetuximab + FOLFIRI)

Population

BRAF V600E-mutant metastatic CRC, 2L (1–2 prior lines), RAS wild-type.

Key finding

Kopetz 2019 (interim, triplet primary endpoint): triplet vs control: median OS 9.0 vs 5.4 months (HR 0.52, 95% CI 0.39–0.70; P<0.001); ORR 26% vs 2% (P<0.001); doublet (encorafenib+cetuximab) OS 8.4 months (HR 0.60, 95% CI 0.45–0.79; P<0.001). Tabernero 2021 (final analysis): doublet median OS 9.3 months (95% CI 8.0–11.3) vs control 5.9 months (95% CI 5.1–7.1) (HR 0.60 [0.47–0.75]); triplet OS 9.3 months (8.2–10.8); grade ≥3 AEs: triplet 58%, doublet 50%, control 61%.

Source: PMID 31566309

Timeline

    Guideline citations

    • NCCN Colon (p.148)